In short
Diagnosing medullary thyroid cancer involves a careful process of examination, imaging, and laboratory testing. Because this rare form of thyroid cancer originates from specialized cells and can sometimes run in families, the diagnostic approach differs from other thyroid cancers and includes genetic screening to identify hereditary forms.
Key points
- A persistent lump in the neck is the most common sign of medullary thyroid cancer, but many people have no symptoms for a long time because the tumor stays small.
- Blood tests measuring calcitonin and CEA levels are uniquely important for diagnosing medullary thyroid cancer and cannot be replaced by imaging alone.
- Up to 25% of medullary thyroid cancer cases are hereditary, making genetic testing essential for all patients diagnosed with this cancer.
- Finding a RET gene mutation means your close family members should be tested too, as they may be able to prevent cancer through early thyroid removal.
- If you have hereditary medullary thyroid cancer, you must be screened for pheochromocytomas before any thyroid surgery because these adrenal tumors can cause life-threatening complications.
- Unlike other thyroid cancers, medullary thyroid cancer does not absorb radioactive iodine, which is why complete surgical removal at the first operation is so important.
- Most patients with medullary thyroid cancer have excellent long-term survival, with five-year survival rates ranging from 87% to 92%.
- Clinical trials for medullary thyroid cancer require standardized diagnostic tests including imaging, tumor marker measurements, and often molecular testing of the cancer tissue.
Introduction: Who Should Seek Diagnostics
People who notice a lump or swelling in the front part of the neck, just below the Adam's apple, should seek medical evaluation. This is especially important if the lump persists or grows over time. Anyone who experiences persistent hoarseness that doesn't go away, difficulty swallowing, a sore throat that doesn't improve, or pain in the neck should also consult a healthcare provider right away.
Sometimes, healthcare providers discover thyroid nodules during routine physical examinations when they feel the neck area. In other cases, imaging tests performed for completely unrelated reasons may accidentally reveal a thyroid nodule. Even when there are no symptoms, such findings warrant further investigation.
People with a family history of medullary thyroid cancer or related genetic conditions should be particularly vigilant. Up to one in four cases of medullary thyroid cancer are hereditary, meaning they run in families. If a close family member such as a parent, sibling, or child has been diagnosed with medullary thyroid cancer, other family members may benefit from genetic screening even before symptoms appear.
Classic Diagnostic Methods
When medullary thyroid cancer is suspected, doctors follow a systematic approach to confirm the diagnosis and understand the extent of the disease. The process typically begins with a complete medical history and physical examination, during which the doctor will carefully feel the neck to check for lumps or enlarged lymph nodes.
Imaging Tests
Imaging tests create pictures of the inside of the body and help identify nodules on the thyroid gland. The first imaging test is usually a thyroid ultrasound, which uses sound waves to create detailed images. This test helps determine the size, shape, and characteristics of any thyroid nodules. Ultrasound can also reveal whether lymph nodes in the neck appear abnormal or enlarged, which might indicate that cancer has spread.
If the ultrasound suggests a problem, additional imaging may be needed. A CT scan (computed tomography) or MRI (magnetic resonance imaging) can provide more detailed views of the thyroid and surrounding structures. These tests help doctors see if the cancer has grown into nearby tissues or spread to other parts of the neck.
Fine Needle Aspiration Biopsy
The most definitive way to diagnose medullary thyroid cancer is through a fine needle aspiration biopsy, often shortened to FNA. During this procedure, the doctor uses a very thin needle to remove a small sample of cells from the thyroid nodule. The needle is so thin that the procedure typically causes minimal discomfort, similar to having blood drawn. Sometimes doctors use ultrasound guidance during the biopsy to ensure they're sampling the right area.
After collecting the sample, a specialist called a pathologist examines the cells under a microscope. The pathologist looks for cancer cells and determines what type of thyroid cancer is present. Medullary thyroid cancer has distinctive features that help pathologists identify it. Sometimes, additional testing called immunohistochemical staining is performed on the biopsy sample to look for calcitonin, which is the hormone produced by the C cells where medullary thyroid cancer originates.
Blood Tests
Blood tests play a particularly important role in diagnosing medullary thyroid cancer because the cancer cells produce specific substances that can be measured. The two most important blood tests measure levels of calcitonin and carcinoembryonic antigen, abbreviated as CEA. Calcitonin is a hormone normally made by the C cells of the thyroid, and CEA is a protein that can be elevated in certain cancers.
People with medullary thyroid cancer typically have elevated levels of both calcitonin and CEA in their blood. These markers are so characteristic of medullary thyroid cancer that measuring them helps confirm the diagnosis. The levels of these markers also provide information about how much cancer is present and can be used later to monitor whether treatment is working or if the cancer comes back after treatment.
Other blood tests may measure thyroid hormone levels to check how well the thyroid gland is functioning. However, most people with small medullary thyroid cancers have normal thyroid function because the cancer affects only the C cells, not the cells that produce thyroid hormone.
Genetic Testing
Because up to 25% of medullary thyroid cancer cases are hereditary, genetic testing is an essential part of the diagnostic process. All patients diagnosed with medullary thyroid cancer should be offered genetic testing for mutations in a gene called the RET proto-oncogene. This gene, when mutated, can cause hereditary forms of medullary thyroid cancer, either alone or as part of syndromes called multiple endocrine neoplasia type 2A (MEN2A) and multiple endocrine neoplasia type 2B (MEN2B).
Finding a RET gene mutation is important for several reasons. First, it means that family members should also be tested, as they may have inherited the same mutation and could develop medullary thyroid cancer themselves. Second, people with certain RET mutations may need to be checked for other tumors that can occur as part of MEN syndromes, particularly pheochromocytomas, which are tumors of the adrenal glands that can be life-threatening if not identified and treated.
A genetic counselor often helps patients understand genetic testing, what the results mean, and how to communicate with family members who may also need testing. Even patients without a known family history should undergo genetic testing because they might be the first person in their family to be diagnosed with this hereditary condition.
Additional Screening for MEN Syndromes
When genetic testing reveals a hereditary form of medullary thyroid cancer, particularly MEN2A or MEN2B, patients need additional tests to check for other tumors associated with these syndromes. For MEN2A, this includes screening for pheochromocytomas and parathyroid adenomas, which are tumors of the parathyroid glands. For MEN2B, screening includes checking for pheochromocytomas and examining the mouth and digestive tract for neuromas, which are benign nerve tissue growths.
Screening for pheochromocytomas typically involves blood or urine tests to measure certain hormones and chemicals. If these tests suggest a pheochromocytoma might be present, imaging tests of the adrenal glands are performed. Parathyroid screening usually involves blood tests to measure calcium and parathyroid hormone levels.
Diagnostics for Clinical Trial Qualification
When patients with medullary thyroid cancer are being considered for enrollment in clinical trials, they typically need to undergo a standardized set of diagnostic tests. These tests help researchers ensure that all participants in a study have similar disease characteristics and allow them to accurately measure whether an experimental treatment is working.
The baseline diagnostic workup for clinical trials usually includes a complete physical examination with careful documentation of any palpable nodules or lymph nodes. High-resolution ultrasound of the neck is standard to measure the size and characteristics of the primary tumor and any involved lymph nodes. These measurements provide a starting point for comparing changes during treatment.
Blood tests measuring calcitonin and CEA levels are essential for trial enrollment. These tumor markers not only help confirm the diagnosis but also serve as important measures of treatment response. Many clinical trials require that participants have measurable elevations of these markers to be eligible. The baseline levels are recorded and tracked throughout the trial to see if they decrease with treatment.
Imaging studies beyond ultrasound may be required depending on the trial protocol. CT scans of the chest, abdomen, and pelvis help identify whether cancer has spread to distant sites such as the lungs, liver, or bones. Some trials may also require specialized imaging such as positron emission tomography (PET) scans, which can detect metabolically active cancer cells throughout the body.
For trials testing treatments that target specific genetic mutations, molecular testing of the tumor is required. This involves analyzing tissue from the biopsy or surgery to identify exactly which genetic changes are present in the cancer cells. For medullary thyroid cancer, this often includes detailed analysis of RET gene mutations, as many newer treatments specifically target tumors with these mutations.
Clinical trials may also require baseline assessment of heart and lung function, liver and kidney function, and blood counts to ensure that participants can safely tolerate the experimental treatment. Additional specialized tests might include evaluation of vocal cord function through laryngoscopy, particularly if the tumor is near the nerves that control the vocal cords.
Prognosis and Survival Rate
Prognosis
The prognosis for people with medullary thyroid cancer is generally very good, especially when the cancer is diagnosed early and can be completely removed with surgery. Several factors influence how well a patient will do. The stage of the cancer at diagnosis is one of the most important factors. Patients whose cancer is confined to the thyroid gland have an excellent prognosis, while those whose cancer has spread to lymph nodes or distant organs face more challenges. The completeness of surgical removal also significantly affects outcomes. Because medullary thyroid cancer does not respond to radioactive iodine therapy like other thyroid cancers do, achieving complete surgical removal at the first operation is crucial for the best possible outcome.
Whether the cancer is sporadic or hereditary also influences prognosis. People with hereditary medullary thyroid cancer who are identified through genetic screening before they develop symptoms and undergo preventive thyroid removal have an excellent prognosis. Those diagnosed at a young age with hereditary forms may need more extensive treatment but can still do very well with appropriate care. The levels of calcitonin and CEA tumor markers after surgery provide important information about prognosis. Patients whose marker levels return to normal after surgery generally have better outcomes than those with persistently elevated levels.
Survival Rate
Most patients with medullary thyroid cancer have excellent long-term survival. Overall, the five-year survival rate for people with medullary thyroid cancer ranges from 87% to 92%. The ten-year survival rate remains high at approximately 87%. These survival rates are quite favorable compared to many other types of cancer, though they are somewhat lower than those for the more common forms of thyroid cancer like papillary and follicular thyroid cancer.
Survival rates vary significantly depending on the stage of cancer at diagnosis. Patients with localized disease that has not spread beyond the thyroid have the best outcomes. Even patients with regional disease that has spread to nearby lymph nodes can achieve good long-term survival with appropriate treatment. However, patients whose cancer has spread to distant sites such as the lungs, liver, or bones face more challenges. Despite advances in treatment, medullary thyroid cancer accounts for approximately 13% of thyroid cancer-related deaths, indicating that while most patients do very well, the disease can be serious in some cases.
